Coloplast A/S Series B,

Coloplast is a supplier of intimate healthcare products and services. Co. develops and markets products that support people with diseases of a private nature. Co. operates in three business areas: Ostomy care, products for people whose intestinal outlet has been rerouted through the abdominal wall; Urology and continence care products, for people suffering from diseases of the kidneys, the urinary system and the male reproductive system; Dressings, for the treatment of chronic wounds and skin care products for prevention and treatment. Co. markets and sells its products and services globally. Co. supplies products to hospitals, institutions as well as wholesalers and retailers.
  • TickerCOLO B
  • ISINDK0060448595
  • ExchangeNasdaq Nordic Copenhagen
  • SectorHealth Care Equipment & Services
  • CountryDenmark

Analysts

Frank Maaø ...
  • Håkon Astrup
  • Karl-Johan Bonnevier
  • Martin Arnell
  • Mattias Holmberg
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Paul Harper
  • Rune Majlund Dahl
  • Simen Mortensen

Northern Lights

Debbie Wang

Morningstar | Coloplast Sees More Opportunity in the U.S. and Potential Pressure in France

Coloplast’s solid fiscal second-quarter results generally fell in line with our top- and bottom-line expectations, and we’re leaving our fair value estimate unchanged. We think Coloplast’s narrow economic moat remains in fine shape, as the firm has been rolling out a steady stream of new products, supported by excellent commercial execution. We’ve long been fans of the ostomy and continence care businesses, which seem to be the moatiest thanks to deep end-user loyalty. However, the firm has even been succeeding and taking share in the no-moat advanced wound care (AWC) market, especially under ...

Debbie Wang

Morningstar | Coloplast Sees More Opportunity in the U.S. and Potential Pressure in France

Coloplast’s solid fiscal second-quarter results generally fell in line with our top- and bottom-line expectations, and we’re leaving our fair value estimate unchanged. We think Coloplast’s narrow economic moat remains in fine shape, as the firm has been rolling out a steady stream of new products, supported by excellent commercial execution. We’ve long been fans of the ostomy and continence care businesses, which seem to be the moatiest thanks to deep end-user loyalty. However, the firm has even been succeeding and taking share in the no-moat advanced wound care (AWC) market, especially under ...

Debbie Wang

Coloplast Sees More Opportunity in the U.S. and Potential Pressure in France

Coloplast’s solid fiscal second-quarter results generally fell in line with our top- and bottom-line expectations, and we’re leaving our fair value estimate unchanged. We think Coloplast’s narrow economic moat remains in fine shape, as the firm has been rolling out a steady stream of new products, supported by excellent commercial execution. We’ve long been fans of the ostomy and continence care businesses, which seem to be the moatiest thanks to deep end-user loyalty. However, the firm has even...

Rune Majlund Dahl

Coloplast (Hold, TP: DKK700.00) - W&S beat – Ostomy miss

With c8% organic growth YOY, Q2 group results were in line but on a divisional level Wound & Skin Care stood out, at c9% growth, while Ostomy disappointed with c6% organic growth. The 2018/19 organic growth guidance was unchanged at c8% but upped to c9% in DKK. The EBIT margin guidance was unchanged at 31–32% (c31% in DKK). With only minor estimate changes, we retain our HOLD and DKK700 target price.

Rune Majlund Dahl

Coloplast (Hold, TP: DKK700.00) - 8% organic growth again

Coloplast again achieved c8% organic growth YOY in Q2 2018/19, in line with our estimate and consensus, but just missed on reported growth due to FX. EBIT came in above our forecast and consensus as the margin surprised on the upside. The 2018/19 guidance was unchanged at c8% organic growth, but upped in local currency to 9% (8–9%), with an EBIT margin of 30–31% (c31% in DKK).

Rune Majlund Dahl

Coloplast (Hold, TP: DKK700.00) - Tough comparables in Q2

We forecast organic revenue growth of 8.1% in Q2 (results due around noon CET on 2 May), in line with the c8% full-year guidance. We expect continued solid underlying growth in Ostomy but highlight tough YOY comparables, especially in emerging markets. We expect investments to be front-end loaded in 2018/19 and forecast a continued high level in Q2 and with a moderate FY EBIT margin improvement in H2. We reiterate our HOLD and DKK700 target price.

A director bought 38,300 shares at 521.960DKK and

A director at Coloplast As bought 38,300 shares at 521.960DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boa...

Frank Maaø ...
  • Håkon Astrup
  • Karl-Johan Bonnevier
  • Martin Arnell
  • Mattias Holmberg
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Paul Harper
  • Rune Majlund Dahl
  • Simen Mortensen

Northern Lights

Håkon Astrup ...
  • Nicolas McBeath
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Stefan Gauffin

Northern Lights

Christer Magnergård ...
  • Martin Arnell
  • Mattias Holmberg
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Rune Majlund Dahl

Northern Lights

Christer Magnergård ...
  • Eivind Sars Veddeng
  • Jesper Ingildsen
  • Jon Masdal
  • Karl-Johan Bonnevier
  • Martin Hoang Nguyen
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Simen Mortensen

Northern Lights

Alexander Aukner ...
  • Antti Kansanen
  • Håkon Astrup
  • Helge André Martinsen
  • Jon Masdal
  • Martin Hoang Nguyen
  • Martin Huseby Karlsen
  • Mattias Holmberg
  • Nicolay Dyvik
  • Ole-Andreas Krohn
  • Paul Harper
  • Rune Majlund Dahl

Northern Lights

COLOPLAST A/S reduced its risk exposure resulting in an upgrade to Slightly Positive

COLOPLAST A/S (DK), a company active in the Medical Equipment industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 2 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date April 26, 2019, the closing price was DKK 709.60 and its potential was estimated at DKK 764.26.

Nurhayati Wan

Coloplast

Nurhayati Wan

Coloplast

Nurhayati Wan

Coloplast

Nurhayati Wan

Coloplast

Coloplast – Proxinvest Corporate Governance Rating ® : E

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Expert Corporate Governance Service (ECGS)

Coloplast - 2018, December 5th

In general, Coloplast is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting. On November 1, 2018, the Company announced that Mr. L.S. Rasmussen will resign from his position as CEO to become the new Chairman of the board of directors as of this AGM. Mr. Rasmussen will be succeeded by Executive Vice President - Mr. Kristian Villumsen - as of the same date.   Under ITEM 5.1, it is proposed to re-appoint Mr. N.P. Louis Hansen as Vice Chairman of the board of directors. Although ECGS has no (major) concerns over the re-appointment...

Expert Corporate Governance Service (ECGS)

Etude de l'AG du 07/12/2017

In general, Coloplast is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting.Under ITEMS 5a-5g, the (re-)election of the board of directors is proposed.Under ITEM 5a, it is proposed to re-appoint Mr. Michael Pram Rasmussen as Chairman of the board of directors. Although Mr. Pram Rasmussen is deemed independent, ECGS has various other concerns over his re-appointment. Therefore, ECGS normally would have recommended opposition. However, considering that the proxy card does not permit this, it recommends abstention instead.Under ITEM...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch